Yes, Dexcom continuous glucose monitors are FDA-cleared for type 2 diabetes. The Dexcom G7 is approved for managing diabetes in people aged 2 and older, covering type 1, type 2, and gestational diabetes. Dexcom also makes a second, over-the-counter option called Stelo that’s designed specifically for people with type 2 diabetes who don’t use insulin.
How Dexcom Helps With Type 2 Diabetes
A continuous glucose monitor (CGM) like Dexcom reads your glucose levels every few minutes through a small sensor worn on your body, usually on the back of your upper arm or abdomen. Instead of pricking your finger a few times a day and getting isolated snapshots, you see a continuous stream of data showing how your glucose rises and falls in response to meals, exercise, stress, and sleep.
For people with type 2 diabetes, this real-time feedback changes behavior in ways that fingerstick testing rarely does. You can see exactly what a bowl of rice does to your glucose compared to a salad, or how a 20-minute walk after dinner pulls your levels down. The Dexcom Clarity app stores your historical data so you and your provider can spot patterns over weeks and months, compare time periods before and after making changes, and fine-tune your approach. People who review their Clarity reports at least four times a month spend up to 15% more time in the healthy glucose range (70 to 180 mg/dL) compared to those who don’t check their data.
What the Clinical Evidence Shows
A 12-month randomized trial (the Steno2tech study) compared CGM to traditional fingerstick monitoring in adults with type 2 diabetes on insulin whose blood sugar was not well controlled. The CGM group saw their A1c drop by an additional 0.9 percentage points compared to the fingerstick group. They also spent 15.2% more of their day in the target glucose range, reduced their daily insulin dose by about 10.6 units, and lost an average of 3.3 kilograms (roughly 7 pounds). Participants using CGM also reported better well-being, higher satisfaction with their care, and improved health behaviors.
Even for people with type 2 diabetes on less intensive therapies, the benefits hold up. In a large comparison study published by the American Diabetes Association, people using real-time CGM were significantly more likely to reach an A1c below 7% than those using fingerstick testing alone. Among those on basal insulin, 32.6% of CGM users hit that target compared to 24.1% of fingerstick users. Among those not on insulin at all, 48% of CGM users reached an A1c below 7% versus 41% of fingerstick users.
Dexcom G7 vs. Dexcom Stelo
Dexcom currently offers two CGM options, and which one fits you depends largely on whether you use insulin.
The Dexcom G7 is the full-featured prescription device. It reads glucose between 40 and 400 mg/dL, provides real-time high and low alerts, and can integrate with insulin pumps and connected insulin pens. Each sensor lasts 10 days (plus a 12-hour grace period). It’s designed for anyone with diabetes who needs precise monitoring, especially people managing insulin doses or who are at risk of dangerously low blood sugar.
The Dexcom Stelo is an over-the-counter option available without a prescription, sold directly through Dexcom’s website and at pharmacies. It’s built for adults 18 and older who don’t take insulin and don’t have problems with low blood sugar. That includes people with type 2 diabetes managed through oral medications, diet, and exercise, as well as people with prediabetes. Each sensor lasts 15 days. It reads glucose between 70 and 250 mg/dL and simply displays “below 70” or “above 250” outside that window. It does not have real-time alerts for highs or lows and cannot connect to insulin delivery systems. Think of it as a lifestyle and learning tool rather than a clinical monitoring device.
Prescription and Insurance Coverage
The Dexcom G7 requires a prescription from your doctor. If you’re on insulin or have a documented history of low blood sugar episodes, most insurance plans, including Medicare, will cover it. Medicare’s specific requirements are straightforward: you need to take insulin or have a history of hypoglycemia, your provider needs to order the CGM, and you or your caregiver must have training on how to use it.
If you have type 2 diabetes but don’t use insulin and don’t qualify for a G7 prescription, the Stelo fills that gap. Because it’s sold over the counter, you don’t need insurance approval. The trade-off is that you pay out of pocket and get a device with fewer clinical features.
What Daily Use Looks Like
Both Dexcom devices use a small, discreet sensor about the size of a quarter that sticks to your skin with adhesive. A thin, flexible filament sits just under the skin and measures glucose in the fluid between your cells. You apply a new sensor yourself, which takes about a minute. The sensor pairs with your smartphone via Bluetooth, and readings appear in the Dexcom app throughout the day without you needing to do anything.
For type 2 users, the most valuable feature is often the trend data. The app shows arrows indicating whether your glucose is rising, falling, or holding steady, which helps you make decisions in real time. After a few weeks of wear, most people start recognizing their personal patterns: which foods cause spikes, which types of exercise bring levels down fastest, and how sleep quality affects their morning numbers. The Clarity app lets you pull up comparison charts to see whether changes you’ve made are actually working, and your provider can access the same reports during appointments to adjust your treatment plan with far more data than a quarterly A1c test provides.
The G7 is cleared to replace fingerstick testing entirely for treatment decisions. You can use it to decide on insulin doses without confirming with a finger prick, which simplifies daily management considerably for people on insulin therapy.